Cantor Fitzgerald analyst Eliana Merle reiterated a Buy rating on AnaptysBio Inc (NASDAQ: ANAB) today and set a price target of $124. The company’s shares opened today at $92.80.
Merle wrote:
“. We reiterate our Overweight rating and 12-month PT of $124. Ahead of the topline data, we did an analysis of FEV1 (a measure of respiratory capacity) data seen in other early stage asthma trials of drugs that are now approved for asthma (chart on pg. 4/below). We caveat this with the fact that there are many limitations of cross trial comparisons and that many of these studies were in multi- dose studies (vs. ANAB’s single dose).”
Currently, the analyst consensus on AnaptysBio Inc is a Strong Buy with an average price target of $117.80, which is a 26.9% upside from current levels. In a report issued on September 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $127 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $134 and a one-year low of $33.57. Currently, AnaptysBio Inc has an average volume of 322K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANAB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
